导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.44% | 2092/4773 |
| 近一周 | -1.83% | 771/5462 |
| 近一月 | 0.42% | 604/5421 |
| 近一季 | -0.52% | 851/5209 |
| 近半年 | -5.95% | 2978/4920 |
| 近一年 | 0.83% | 2471/4366 |
| 近两年 | 21.32% | 2625/2954 |
| 近三年 | 14.02% | 1657/2253 |
| 成立以来 | 415.60% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.35% 742/4961 |
-9.97% 4014/5312 |
- - |
- - |
| 2025 | 5.09% 3014/4813 |
-2.37% 2879/3635 |
3.98% 890/4076 |
2.01% 3842/4524 |
1.48% 1362/4813 |
| 2024 | 12.26% 1259/3463 |
7.21% 254/2808 |
1.90% 430/3014 |
5.89% 2872/3129 |
-2.97% 2221/3463 |
| 2023 | 6.94% 158/2656 |
5.51% 781/2280 |
2.09% 166/2385 |
3.07% 202/2515 |
-3.67% 758/2655 |
| 2022 | -3.55% 67/2207 |
1.41% 103/1919 |
0.19% 1575/2016 |
-3.76% 41/2113 |
-1.36% 1694/2208 |
| 2021 | 17.40% 233/1822 |
6.29% 95/1255 |
6.94% 712/1330 |
4.50% 345/1466 |
-1.16% 1320/1822 |
| 2020 | 7.92% 860/1250 |
-9.62% 697/1028 |
4.98% 895/1067 |
9.29% 659/1164 |
4.07% 871/1184 |
| 2019 | 20.58% 662/1092 |
20.58% 607/754 |
-4.05% 417/804 |
-1.98% 683/850 |
6.32% 627/918 |
| 2018 | -16.35% 107/834 |
- - |
- - |
- - |
-7.94% 76/691 |
| 2017 | 23.24% 139/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.13% 117/605 |
- - |
- - |
- - |
- - |
| 2015 | 30.30% 75/575 |
- - |
- - |
- - |
- - |
| 2014 | 48.47% 95/237 |
- - |
- - |
- - |
- - |
| 2013 | -6.92% 119/186 |
- - |
- - |
- - |
- - |
| 2012 | 10.09% 41/140 |
- - |
- - |
- - |
- - |
| 2011 | -15.69% 9/102 |
- - |
- - |
- - |
- - |
| 2010 | -9.24% 20/58 |
- - |
- - |
- - |
- - |
| 2009 | 67.83% 25/27 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 富国中证红利指数增强A VS. 长安沪深300非周期A(740101) |